Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.61 -0.7%	$3.13	$0.92 ▼ $4.08	$950.74M	0.88	3.16 million shs	1.57 million shs
ALT Altimmune	$4.76 -2.9%	$5.70	$2.90 ▼ $11.16	$386.07M	0.47	3.34 million shs	6.33 million shs
INZY Inozyme Pharma	$4.00	$3.21	$0.72 ▼ $6.24	$258.25M	2.27	927,189 shs	N/A
KALA KALA BIO	$5.29 +4.8%	$4.07	$2.92 ▼ $11.20	$32.91M	-1.88	45,631 shs	54,938 shs
VKTX Viking Therapeutics	$28.16 +1.6%	$27.42	$18.92 ▼ $81.73	$3.17B	0.62	4.04 million shs	2.38 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	0.00%	-1.23%	-2.30%	+103.67%	+280.88%
ALT Altimmune	0.00%	+36.00%	-12.82%	+12.26%	-27.88%
INZY Inozyme Pharma	0.00%	+0.25%	+0.25%	+387.09%	-10.91%
KALA KALA BIO	0.00%	+14.50%	+26.86%	+24.76%	-22.43%
VKTX Viking Therapeutics	0.00%	+6.18%	+4.14%	+24.49%	-44.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	4.2557 of 5 stars	3.6	4.0	4.0	2.0	0.8	0.6
ALT Altimmune	2.2318 of 5 stars	3.5	1.0	0.0	2.5	1.7	0.6
INZY Inozyme Pharma	3.4194 of 5 stars	4.2	4.0	0.0	1.9	2.5	0.0
KALA KALA BIO	3.3798 of 5 stars	3.5	1.0	4.4	0.0	0.8	0.6
VKTX Viking Therapeutics	4.3571 of 5 stars	4.5	1.0	4.7	1.9	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.20	Buy	$6.75	87.24% Upside
ALT Altimmune	3.00	Buy	$19.00	299.16% Upside
INZY Inozyme Pharma	2.44	Hold	$11.75	193.75% Upside
KALA KALA BIO	3.00	Buy	$13.50	155.20% Upside
VKTX Viking Therapeutics	3.00	Buy	$87.15	209.50% Upside

Current Analyst Ratings Breakdown

Latest AKBA, VKTX, INZY, KALA, and ALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	ALT Altimmune	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/27/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
6/25/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
6/2/2025	KALA KALA BIO	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
5/23/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
5/16/2025	INZY Inozyme Pharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00
5/16/2025	INZY Inozyme Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$15.00 ➝ $4.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$184.91M	5.12	N/A	N/A	($0.23) per share	-15.67
ALT Altimmune	$20K	19,304.18	N/A	N/A	$1.74 per share	2.74
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	$0.90 per share	N/A
KALA KALA BIO	N/A	N/A	N/A	N/A	$2.02 per share	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$7.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$69.41M	-$0.21	N/A	N/A	N/A	-24.51%	N/A	-18.92%	8/6/2025 (Estimated)
ALT Altimmune	-$95.06M	-$1.26	N/A	N/A	N/A	-451,200.00%	-65.44%	-58.43%	8/6/2025 (Estimated)
INZY Inozyme Pharma	-$102.02M	-$1.69	N/A	N/A	N/A	N/A	-159.93%	-82.48%	8/5/2025 (Estimated)
KALA KALA BIO	-$38.51M	-$8.24	N/A	N/A	N/A	N/A	-369.29%	-64.99%	8/5/2025 (Estimated)
VKTX Viking Therapeutics	-$109.96M	-$1.15	N/A	N/A	N/A	N/A	-14.41%	-14.02%	7/23/2025 (Estimated)

Latest AKBA, VKTX, INZY, KALA, and ALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/23/2025	Q2 2025	VKTX Viking Therapeutics	-$0.44	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	INZY Inozyme Pharma	-$0.43	-$0.44	-$0.01	-$0.44	N/A	N/A
5/13/2025	Q1 2025	ALT Altimmune	-$0.35	-$0.26	+$0.09	-$0.26	$0.00 million	$0.01 million
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
4/23/2025	Q1 2025	VKTX Viking Therapeutics	-$0.31	-$0.41	-$0.10	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A
KALA KALA BIO	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	1.89	2.23	2.02
ALT Altimmune	N/A	15.85	15.85
INZY Inozyme Pharma	0.65	2.19	2.19
KALA KALA BIO	3.19	1.99	1.99
VKTX Viking Therapeutics	N/A	44.25	44.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
ALT Altimmune	78.05%
INZY Inozyme Pharma	88.30%
KALA KALA BIO	24.61%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
ALT Altimmune	4.10%
INZY Inozyme Pharma	12.18%
KALA KALA BIO	8.32%
VKTX Viking Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	262.64 million	254.76 million	Optionable
ALT Altimmune	50	81.11 million	77.78 million	Optionable
INZY Inozyme Pharma	50	64.56 million	56.70 million	Optionable
KALA KALA BIO	30	6.45 million	5.92 million	Not Optionable
VKTX Viking Therapeutics	20	112.31 million	107.71 million	Optionable

AKBA, VKTX, INZY, KALA, and ALT Headlines

Recent News About These Companies

August 22nd Options Now Available For Viking Therapeutics (VKTX)

July 5 at 10:21 AM | nasdaq.com

Insider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells 4,266 Shares of Stock

July 4 at 8:07 AM | insidertrades.com

Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity

July 4 at 4:30 AM | fool.com

Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts

July 3 at 6:46 PM | zacks.com

Insider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells 4,266 Shares of Stock

July 3 at 6:41 PM | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) COO Sells $118,466.82 in Stock

July 3 at 6:41 PM | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) CEO Sells 26,889 Shares

July 3 at 6:25 PM | marketbeat.com

VKTX - Viking Therapeutics Inc Sustainability - Morningstar

July 3 at 5:18 AM | morningstar.comM

H.C. Wainwright Keeps Their Buy Rating on Viking Therapeutics (VKTX)

July 2, 2025 | theglobeandmail.com

Viking Therapeutics (NASDAQ:VKTX) Shares Up 7.7% - Here's What Happened

July 2, 2025 | marketbeat.com

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

July 2, 2025 | zacks.com

Got $200? 2 Biotech Stocks to Buy and Hold Forever

July 1, 2025 | fool.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Rating of "Buy" by Brokerages

July 1, 2025 | marketbeat.com

3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

...

June 29, 2025 | marketbeat.com

Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note

June 27, 2025 | zacks.com

HC Wainwright Reiterates "Buy" Rating for Viking Therapeutics (NASDAQ:VKTX)

June 27, 2025 | americanbankingnews.com

Why This Weight Loss Drug Company's Stock Surged Today

June 26, 2025 | fool.com

VKTX Initiates Phase 3 Study on Obesity Candidate VK2735

June 26, 2025 | zacks.com

VKTX Viking Therapeutics, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Stock Holdings Increased by International Assets Investment Management LLC

June 26, 2025 | marketbeat.com

Oppenheimer & Co. Inc. Acquires 23,481 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 26, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
By Chris Markoch | June 29, 2025
View 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

AKBA, VKTX, INZY, KALA, and ALT Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.60 -0.03 (-0.69%)

Closing price 07/3/2025 02:45 PM Eastern

Extended Trading

$3.62 +0.01 (+0.28%)

As of 07/3/2025 04:58 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Altimmune NASDAQ:ALT

$4.76 -0.14 (-2.86%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$4.76 +0.00 (+0.08%)

As of 07/3/2025 04:59 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Inozyme Pharma NASDAQ:INZY

$4.00 0.00 (0.00%)

As of 07/1/2025

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

KALA BIO NASDAQ:KALA

$5.29 +0.24 (+4.75%)

Closing price 07/3/2025 03:44 PM Eastern

Extended Trading

$5.17 -0.12 (-2.34%)

As of 07/3/2025 04:01 PM Eastern

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Viking Therapeutics NASDAQ:VKTX

$28.16 +0.44 (+1.59%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$28.04 -0.12 (-0.43%)

As of 07/3/2025 04:56 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time